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S U M M A R Y
Background: Mediastinitis is a serious complication after cardiac surgery. While bacteria are the more
common pathogens, fungal infections are rare. In particular, several cases of postoperative Aspergillus
mediastinitis have been reported, the majority of which had an extremely poor outcome.
Methods: A case of mediastinitis in a 42-year-old patient due to Aspergillus fumigatus after cardiac
surgery is described. Two main risk factors were found: cardiogenic shock requiring veno-arterial
extracorporeal life support and failure of primary closure of the sternum. A full recovery was attained
after surgical drainage and antifungal therapy with liposomal amphotericin B, followed by a
combination of voriconazole and caspofungin. The patient was followed for 18 months without relapse.
Results: This is an extremely rare case of postoperative Aspergillus mediastinitis exhibiting a favourable
outcome. Based on a systematic review of the literature, previous cases were examined with a focus on
risk factors, antifungal therapies, and outcomes.
Conclusion: The clinical features of postoperative Aspergillus mediastinitis may be paucisymptomatic,
emphasizing the need for a low index of suspicion in cases of culture-negative mediastinitis or in
indolent wound infections. In addition to surgical debridement, the central component of antifungal
therapy should include amphotericin B or voriconazole.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Mediastinitis is a feared complication of open heart surgery.
Most commonly due to Staphylococcus spp or Enterobacteriaceae,
non-bacterial pathogens are rare. Several cases of postoperative
Aspergillus mediastinitis have been described in the literature in
immunocompetent patients or after heart transplantation. The
patient outcome after such a complication is extremely poor
despite antifungal therapy and surgery.1
The third reported case of postoperative Aspergillus medias-
tinitis in an immunocompetent adult patient who had a favourable
outcome is described herein. A review of the literature showed that
successful treatment is exceedingly rare and that the optimal
antifungal therapy needs to be determined.* Corresponding author. Tel.: +33 149814974; fax: +33 149812988.
E-mail address: nicolas.mongardon@aphp.fr (N. Mongardon).
http://dx.doi.org/10.1016/j.ijid.2016.01.014
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2. Case report
A 42-year-old woman with a history of three open heart surgeries
for mitral and aortic valve replacements was admitted to the
intensive care unit (ICU) after her fourth double valve replacement.
Anaesthetic interventions were uneventful, including antibiotic
prophylaxis with cefamandole. Veno-arterial extracorporeal life
support (ECLS) was initiated immediately after surgery due to
biventricular failure. The patient’s postoperative course was
complicated by cardiac tamponade on postoperative day (POD) 1,
requiring surgical drainage; primary closure of the sternum was not
possible due to signiﬁcant myocardial oedema, necessitating a latex
patch sutured to the skin. She received a 7-day course of imipenem
for ventilator-associated pneumonia due to extended-spectrum
beta-lactamase-producing Enterobacter cloacae . After a week, she
was successfully weaned off ECLS, and sternal closure was achieved
on POD 16, under imipenem and vancomycin prophylaxis. During
this procedure, samples from the surgical site were systematicallyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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there were no clinical or biological signs of an underlying infectious
process.
All surgical samples including sternal and pericardial tissues
were positive for hyphae under direct visualization, compatible
with Aspergillus spp. Cultures returned positive for several
colonies of Aspergillus fumigatus; no bacteria were isolated. An
extensive search for possible environmental contamination did
not reveal any source in the operating room or in the ICU. An
external fan that was used to cool the patient during a summer
heat wave was suspected to be the source of contamination. The
fan was not cultured due to the delay from the time it was used
for the patient. No other patient undergoing cardiac surgeryTable 1
Main characteristics of patients with mediastinitis due to Aspergillus spp after cardiac s
Ref. Age (years)
and sex
Surgical
procedure
Immuno-
deﬁciency
Risk factors 
8 51, M Heart
transplantation
Yes Immunosuppressive agents 
9 64, M Valvular surgery No Urgent surgery, COPD 
10 46, M Valvular surgery No - 
72, F Coronary artery
bypass graft
No - 
11 61, M Heart
transplantation
Yes COPD, immunosuppressive
agents
12 51, F Heart
transplantation
Yes Multiple redo-surgeries,
immunosuppressive agents
13 3, F Repair of
congenital
cardiomyopathy
No Multiple
redo-
surgeries
6 mo, F No Multiple redo-surgeries,
ECMO, delayed sternal
closure
1 mo, M No Multiple redo-surgeries,
delayed sternal closure
14 60, M Coronary artery
bypass graft
No Diabetes mellitus 
15 61, M Heart
transplantation
Yes Redo-surgery, septic shock,
immunosuppressive agents
16 63, M Aortic dissection No Delayed sternal closure,
hemodynamic instability
17 68, M Pulmonary
endarterectomy
No Pulmonary hypertension,
candidemia
prior to
surgery
18 57, M Coronary artery
bypass graft
No Diabetes mellitus, redo-
surgery
57, F Heart
transplantation
Yes Immunosuppressive
agents, haemodialysis,
COPD
19 55, F Heart
transplantation
Yes Redo-surgery,
immunosuppressive
agents, haemodialysis,
cardiogenic shock
Present
case
42, F Valvular surgery No Multiple redo-surgeries,
delayed sternal closure,
cardiogenic shock
M, male; F, female; NA, not available; COPD, chronic obstructive pulmonary disease; Isince the year prior to this case and to date has developed
postoperative mediastinitis or another invasive Aspergillus
infection.
Intravenous (IV) liposomal amphotericin B at 3 mg/kg daily was
started on POD 17 for 7 days, followed by IV voriconazole at
2.5 mg/kg twice daily (POD 23), adjusted according to plasma
levels. Ten days after the initiation of treatment (POD 27), cultures
from the surgical drains were still positive for fungi, therefore
IV caspofungin (70 mg on the ﬁrst day followed by 50 mg daily)
was added to IV voriconazole (POD 28) for an additional period of
21 days.
A whole body computed tomography scan showed no sign of
secondary localization of invasive aspergillosis; endocarditis wasurgery
Delay between
surgery and
diagnosis
Aspergillus
species
Antifungal treatment and
duration
Outcome
(Time between
diagnosis and
death/cure)
NA A. fumigatus None Death
(Unknown)
12 days A. ﬂavus Amphotericin B Death
(19 days)
NA A. fumigatus NA Death
(Unknown)
NA A. ﬂavus NA Cure
(Unknown)
5 weeks A. fumigatus Voriconazole 200 mg twice
daily indeﬁnitely
Cure
(13 months
of treatment)
2 months A. fumigatus Liposomal amphotericin B
5 mg/kg daily + caspofungin
35 mg daily
Then voriconazole 400 mg
daily
6 months total
Cure
(6 months)
5 months A. fumigatus IV caspofungin
6 months + oral
voriconazole 8 months
Cure
(14 months)
<1 month Aspergillus spp None (post-mortem
diagnosis)
Death
(16 days)
1 month A. fumigatus Liposomal amphotericin
B + caspofungin 1 week
after
Death
(23 days)
2 months A. fumigatus NA Cure
(4 weeks)
1 month A. fumigatus NA Death
(Unknown)
34 days A. fumigatus NA Death
(43 days)
8 days A ﬂavus Liposomal amphotericin B
3 mg/kg
daily + voriconazole 4 mg/
kg daily
Death
(26 days)
6 days A. fumigatus,
A. ﬂavus
Caspofungin Death
(Unknown)
49 days A. fumigatus,
A. terreus
Caspofungin + voriconazole Cure
(Unknown)
5 weeks A. calidoustus Posaconazole
11 days + voriconazole
10 days + amphotericin B
42 days
Cure
(4 months)
16 days A. fumigatus Liposomal amphotericin B
3 mg/kg daily
Then IV voriconazole
200 mg twice
daily + caspofungin 50 mg
daily
Then voriconazole 200 mg
twice daily
Cure
(18 months)
V, intravenous; ECMO, extracorporeal membrane oxygenation.
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beta-D-glucan test was negative, but this became positive (200 pg/
ml) 2 weeks later (POD 30); galactomannan antigenemia was
negative. Galactomannan, beta-D-glucan, and surgical drains were
tested twice weekly for fungi, and the drains were progressively
removed after two consecutive negative cultures, with the last
drain removed after 18 days of combined therapy (POD 47). Since
the patient continued to improve clinically, caspofungin was
discontinued (POD 50) and IV voriconazole was transitioned to oral
treatment (POD 52) for a total of 3 months. Microbiological
monitoring with serial beta-D-glucan testing remained negative
during the 18-month follow-up period. The patient experienced no
relapse during this period and recovered fully.
3. Discussion
Mediastinitis is a rare complication occurring in 1–2% of cases
after sternotomy for cardiac surgery and carries a high mortality
rate. Diagnostic criteria include positive culture from mediastinal
tissue or ﬂuid, evidence of mediastinitis on gross anatomic or
histopathological examination, and at least one of the following
signs or symptoms: fever, chest pain, and sternal instability, with
either purulent drainage from the mediastinal area or mediastinal
widening on imaging.
The most common pathogens are Staphylococcus spp and
Enterobacteriaceae, and fungal pathogens are extremely rare,
predominantly Candida spp. Nevertheless, invasive aspergillosis
is an emerging entity in non-immunocompromised patients,
especially after major cardiovascular and ophthalmological
surgeries.1 In the literature, postoperative Aspergillus mediasti-
nitis has been reported in only 16 cases, including six in
immunocompromised patients after heart transplantation and
10 in immunocompetent patients (Table 1 8–19). The diagnosis is
often delayed and has relied on direct visualization and culture
until recently. Although galactomannan and beta-D-glucan tests
are non-speciﬁc and cannot be used for diagnosis, they can be
useful for monitoring fungal infections.2
Only two previous cases of postoperative Aspergillus
mediastinitis in immunocompetent adults have had a favourable
outcome. Interestingly, immunocompromised patients appear to
have better outcomes (4/6 surviving) than immunocompetent
patients (2/10 surviving), suggesting a delay in reaching a
diagnosis and the need for earlier treatment. Although the
patient presented here was not immunosuppressed in the
traditional sense, it is well established that critically ill patients
are prone to healthcare-associated infections due to transient
immunosuppression following major surgery. Given the exceed-
ingly poor outcomes of this type of infection, delineating the
optimal medical therapy is crucial, regardless of the immune
status.
In patients with a favourable outcome, antifungal therapy has
consisted of voriconazole or amphotericin B monotherapy, with
some cases in which caspofungin was added in combination. In the
case presented here, liposomal amphotericin B was the ﬁrst-line
drug, analogous to the treatment of Aspergillus endocarditis, in
which both liposomal amphotericin B and voriconazole are the
therapeutic options.3,4 As endocarditis was ruled out, voriconazole
was selected due to its efﬁcacy against Aspergillus spp.3 However,
persistently positive surgical drain fungal cultures led to the
coverage being reinforced with caspofungin. Indeed, caspofungin
was chosen as adjuvant therapy because of the presence of a
mechanical cardiac valve and the effect of caspofungin on
bioﬁlms,5 although the requirement for an antifungal combination
is not proven. While long-term treatment with oral voriconazole is
recommended in Aspergillus endocarditis, the treatment duration
in the present patient was relatively short because of the lack ofsigns of recurrence. The short and long-term follow-up conﬁrmed
the effectiveness of this strategy. However, further studies are
needed to better determine the optimal treatment duration and
choice of antifungal therapy, since the currently available data are
restricted to isolated reports.
In this patient, the maintenance of chest opening for over
2 weeks appeared to be the most probable entry site of infection,
despite the latex patch applied to the sternal wound. Contamina-
tion of the surgical site by airborne spores may also have been
favoured by air-mixing due to the external fan. Neither the high-
efﬁciency particulate air-ﬁltering systems nor the areas adjacent to
the cardiac surgery ward seemed to have contributed to this
contamination. Invasive Aspergillus outbreaks, however, have
been described after cardiac surgery due to high levels of airborne
Aspergillus spores. In addition, the severity of organ dysfunction,
reﬂected by the need for prolonged ECLS and mechanical
ventilation, has been found to be a risk factor for aspergillosis.6
Transient immunodeﬁciency after major cardiac surgery and early
re-operation for cardiac tamponade may also have contributed to
the onset of Aspergillus mediastinitis. Although broad-spectrum
antibiotic therapy has been identiﬁed as a risk factor for Candida
infection, this is not a risk factor for invasive aspergillosis.7
In summary, the clinical features of postoperative Aspergillus
mediastinitis may be paucisymptomatic, emphasizing the need for
a low index of suspicion in cases of culture-negative mediastinitis
or in indolent wound infections with no other bacterial growth.
Besides surgical debridement, guidelines for optimal therapy are
needed. Based on the few favourable outcomes, the central
component of antifungal therapy should include amphotericin B
or voriconazole.
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